A Platform Company To Develop Neutralizing mAb To Target Covid-19

Senior Team

Secured Support From Italy & Canada


Cost-efficient Global
Outsourcing Model


About Us

Virna Therapeutics is focused to develop neutralizing monoclonal antibody (mAb) that should prevent the SARS-CoV-2 from entering human host cells to combat the COVID-19, and also its other strains that could emerge as threats in the future.

Virna Therapeutics has brought a multi-national team from USA, Canada, Italy and India to rapidly develop the therapeutic antibodies. The funding by Canadian Govt has been pivotal for discovery work thus far, and ministry of health has extended a full support for rapid development. Government of Italy has extended a full support for manufacturing and clinical development of the antibodies.

Virna has identified an Indian Industry partner, Intonation Research Laboratories, Pvt. Ltd. Hyderabad, for an exclusive development and marketing right for South East Asia. The plan for India is to help in characterizing antibody, parallel scale up and clinical trials.

Three Distinct Approaches to
Block Viral Infection

Validated Antibody
Nucleic Acid
Small Molecule
Protease Inhibitors


Antibody Platform
Screening for other viruses
Over 10,000 antibodies for ~1000 proteins
Developing animal models
Nucleic Acid Therapy
Identified and designed Gap-Mer LNAs using the unique viral sequence
Proof of concept studies in progress
Structure Based Molecule
Identified novel DUBs involved in assembly and release of new virus from infected cell
VLS completed
Validated a robust biochemical

Our Team

Sachdev Sidhu

Dr Sachdev Sidhu

Prof. at University of Toronto and founder of the Toronto Recombinant Antibody Centre (TRAC) for Commercialization of Antibodies and Biologics.

pier paolo

Dr. Pier Paolo Pandolfi

Prof. at Beth Israel Deaconess Medical Center, Harvard Medical School and a preeminent molecular geneticist and cancer biologist.

suresh jain

Dr. Suresh Jain

A successful biotech entrepreneur with an impressive track record of building effective organizations. Founder and former COO and CSO of Acylin Therapeutics.

jang gupta

Dr. Jang B Gupta

An experienced drug discovery scientist and advanced several discovery programs to IND. He was President for a bio-therapeutic CRO in USA. His can be contacted at jgupta@intotech.net
(phone 9866560310)

Advisors and Consultants

yves durocher

Yves Durocher

Section Head, Mammalian Cell Expression National Research Council of Canada

philippe begin

Philippe Bégin

M.D. , FRCPC , Ph.D. Advisor Clinical Affairs Director, Oral Immunotherapy Clinic (CITO), CHU Sainte-Justine Leader CPT - Canadian national effort

giuseppe novelli

Giuseppe Novelli

PhD Advisor, R&D Professor, Med Genetics Tor Vergata Univ of Rome Director, U.O.C. Medical Genetics

Connect With Us

Get In Touch

18 Furbush Road, West Roxbury,
MA 02132
+1 617-249-3402